TMF archiving services for completed clinical studies are the systems and processes sponsors use to keep a Trial Master File (TMF) secure, complete, and inspection-ready for years after a trial ends. In practice, that means read-only access controls, an unbroken audit trail, periodic integrity checks, and a way to retrieve any document quickly if a regulator asks for it — for as long as the applicable retention period requires, which is now as long as 25 years in some jurisdictions.
"Archiving" and "transfer" get used interchangeably, but they're different problems. TMF transfer is the custody handoff — moving a TMF from a CRO back to a sponsor, or from one system to another, usually at a specific milestone (see Kivo's own best practices for end-of-study TMF transfer for that side of it). Archiving is what happens next: once a study is locked and the final TMF is complete, the file moves into a long-term, largely static state where the priority shifts from active document workflows to preservation, access control, and retrievability.
A completed study's TMF still needs to answer, on demand, three questions an inspector or auditor might ask years later: is this the final, unaltered version of every document; who has touched it and when; and can we get to a specific document in minutes, not days. An archiving-specific plan — as opposed to just leaving the TMF wherever it landed at study close — is what keeps those questions answerable.
Retention requirements vary meaningfully by region and by whether the trial supported an approved marketing application, and one of the applicable rules just changed. As of a few months ago, sponsors running trials in the UK are working under a materially longer retention clock than before:
The practical takeaway: if a trial has any EU, UK, or multi-region footprint, 25 years (or "until no longer needed," if that's longer) is the number to plan an archiving strategy around — not the shorter US minimum, which is easy to over-rely on if a program started as domestic-only.
An archived TMF should default to read-only, with access granted by role and, ideally, time-limited for anyone outside a small administrative group. Broad, standing write access to an archived study is itself a finding waiting to happen.
Static storage isn't the same as verified storage. A defensible archive runs periodic checksum or hash verification against every stored document, so bit rot, silent corruption, or an accidental overwrite gets caught before an inspection does.
An inspector's request has a clock on it. Archiving that depends on someone remembering which offline drive or CRO ticket queue holds a given document doesn't hold up — the file needs to be searchable and retrievable by metadata (site, document type, date, TMF Reference Model zone) without a multi-day lookup.
The move into archive status shouldn't create a gap in the record. Who archived it, when, and under what authority should itself be logged — and any prior audit trail (including one recompiled from a legacy system during migration) needs to carry forward intact rather than resetting at the archive boundary.
Most sponsors land on one of three approaches. None is universally wrong, but each carries different tradeoffs — this is a comparison of approaches, not a ranked list, since the right fit depends on trial volume, internal IT resourcing, and how many active vendors are already in the sponsor's document ecosystem.
| Approach | What it looks like | Strengths | Watch out for |
|---|---|---|---|
| Self-managed (in-house) | Sponsor's own IT/QA team maintains storage, access, and integrity checks directly, often on internal infrastructure or a general-purpose cloud storage tool | Full control; no per-study vendor cost | Requires internal expertise in GxP-compliant storage; integrity checks and access reviews often become manual, easy-to-skip processes without dedicated tooling |
| CRO-outsourced storage | The CRO that ran the trial continues to hold the TMF in archive after study close, typically billed per study or per volume | No new system to stand up; CRO already knows the data | Sponsor loses direct oversight and fast self-service retrieval; costs can compound across a growing portfolio of studies and CROs; a documented pattern of the sponsor needing its own visibility even into vendor-held archives |
| Platform-native long-term storage | The same compliant document platform used during the active trial continues to hold the TMF in a locked, read-only archive state | No transfer or re-migration at study close; continuity of the existing audit trail and permissioning; typically no incremental per-study or per-GB charge | Only as good as the platform's own long-term-support commitment — worth confirming retention isn't tied to an active subscription tier that could lapse |
Whichever approach a sponsor leans toward, the same evaluation questions apply:
Kivo's eTMF module includes long-term TMF storage built to support retention windows of 25+ years without a separate archiving migration at study close — because the TMF was already living in Kivo's Part 11-compliant document core, moving it into an archived, read-only state doesn't require moving it anywhere else. Kivo doesn't charge per-GB or per-study for this, which is a deliberate structural difference from outsourcing long-term storage to a CRO, where archiving costs typically scale with the number and size of studies held.
Archived TMFs in Kivo retain role-based access controls, a continuous and uneditable audit trail (including trails recompiled during migration from a prior system), and quarterly data-integrity checks run as checksums against stored documents. Elevar Therapeutics' experience is the clearest quantified proof point here: Elevar migrated 19 TMF studies — 73,794 documents — into Kivo in 72 days, reducing storage cost and simplifying ongoing operations in the process.
None of this requires a new system for sponsors already running their active trial documents in Kivo — archiving is a state change within the same platform, not a migration to a different one.
It depends on the region and whether a marketing application was approved, but 25 years — the ICH E6(R3) floor, now matched by the UK's amended Clinical Trials Regulations as of 28 April 2026 — is the planning figure for any EU, UK, or multi-region trial. US-only requirements can run as short as 2 years past approval.
Not defensibly. An inspector expects to see exactly who could access the archive and under what role, so a secure TMF archive needs the same role-based permissioning as the active trial — narrowed to a small administrative group, not removed, once the study closes and day-to-day document work ends.
Volume mainly changes what to prioritize during evaluation: fast, metadata-driven retrieval (by site, document type, or TMF Reference Model zone) matters more as document counts climb, and per-GB pricing models become materially more expensive at scale than a flat or included-storage structure.
Yes, and it's an advantage rather than a coincidence — retrieval speed built for active trial monitoring doesn't disappear once a study locks, so a platform that's fast during the trial stays fast during the archive period, instead of documents becoming harder to find the moment they're no longer actively worked on.
It means the sponsor — not just the CRO or storage vendor holding the data — keeps direct, role-based visibility into the archive rather than having to request access through a third party. That distinction matters most when the original CRO relationship has ended or changed, since sponsor-side access shouldn't depend on a vendor still being reachable years later.